Stocksigma LogoStocksigma Logo

Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins

Anthem Biosciences reported Q2FY27 consolidated revenue from operations of ₹5,940 Mn, up 7.9% YoY and 42.0% QoQ, driven by CRDMO sales of ₹5,093 Mn (up

Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins

Anthem Biosciences Ltd · Investor Presentation · 03 Nov 2026, 11:43 pm

Anthem Biosciences Reports Strong Q2FY27 Results With Record Margins Anthem Biosciences reported Q2FY27 consolidated revenue from operations of ₹5,940 Mn, up 7.9% YoY and 42.0% QoQ, driven by CRDMO sales of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins expanding 610 bps YoY to 50.6%. PAT increased 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1FY27, revenue reached ₹10,123 Mn, EBITDA stood at ₹5,059 Mn (46.2% margin), and PAT was ₹3,314 Mn. As of 30th Sep'26, net cash totaled ₹15,380 Mn.

Original exchange filing (PDF)

More announcements from Anthem Biosciences Ltd

All Anthem Biosciences Ltd announcements